Drug Search Results
Using advanced filters...
Advanced Search [+]

Sarcolysin

Alternative Names: sarcolysin
Clinical Status: Inactive
Latest Update: 2025-07-08
Latest Update Note: Clinical Trial Update

Product Description

St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Russia

Approved Indications: None

Known Adverse Events: None

Company: City of Hope Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Neuroblastoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Ganglioneuroblastoma|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome

Phase 2: Anemia, Aplastic|Preleukemia|Lymphoma|Chronic Myeloid Leukemia|Lymphoma, Non-Hodgkin|Graft vs Host Disease|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia|Multiple Myeloma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Paroxysmal Hemoglobinuria|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Sarcoma, Myeloid|Adult T-Cell Leukemia-Lymphoma|Neuroblastoma|T-Cell Lymphoma|Plasmablastic Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Myelofibrosis|Thrombocythemia, Essential|Polycythemia Vera|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Anemia, Refractory, with Excess of Blasts|Follicular Lymphoma|Crohn Disease|Thrombocytosis|Lymphoma, B-Cell|Biphenotypic Acute Leukemia|Histiocytosis, Langerhans-Cell|HIV Infections|Myeloid, Accelerated Leukemia|Prolymphocytic B-Cell Leukemia|Leukemia, Plasma Cell|Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia|Prolymphocytic T-Cell Leukemia|Myelodysplastic-Myeloproliferative Diseases|Blast Crisis|B-Cell Leukemia|Myeloproliferative Disorders|Melanoma

Phase 1: Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Sarcoma, Ewing|Myeloproliferative Disorders|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Anemia, Aplastic|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Blast Crisis|Acute Lymphoid Leukemia|Multiple Myeloma|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Chronic Myelomonocytic Leukemia|Preleukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Juvenile Myelomonocytic Leukemia,|Neuroblastoma|Lymphoma|Rhabdoid Tumor|Wilms Tumor|Renal Cell Carcinoma|Myeloid, Accelerated Leukemia|Melanoma|Clear Cell Sarcoma|Biphenotypic Acute Leukemia|Gastrointestinal Cancer|Rhabdomyosarcoma|Adenomyoepithelioma|Clear Cell Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

21D.466

P2

Recruiting

Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Lymphoma, Non-Hodgkin|Acute Myeloid Leukemia|Myelofibrosis|Polycythemia Vera|Multiple Myeloma|Thrombocytosis|Anemia, Aplastic|Adult T-Cell Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Juvenile Myelomonocytic Leukemia,|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Thrombocythemia, Essential

2032-04-01

2025-05-16

NCI-2023-08530

P3

Recruiting

Ganglioneuroblastoma

2029-12-31

2024-11-27

Primary Endpoints|Treatments

MYELOMATCH

P2

Recruiting

Myelodysplastic Syndrome|Acute Myeloid Leukemia

2029-05-15

2025-05-03

2006-7041-83/hah

N/A

Not yet recruiting

Chronic Cough

2023-10-31

NCI-2016-00584

P2

Recruiting

Multiple Myeloma|Biphenotypic Acute Leukemia|Chronic Lymphoid Leukemia|Preleukemia|Acute Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Monocytic Leukemia|Lymphoma, B-Cell|Leukemia, Plasma Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Juvenile Myelomonocytic Leukemia,|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Chronic Myelomonocytic Leukemia|Myeloproliferative Disorders|B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, Non-Hodgkin

2027-05-31

2025-05-10

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

ASCT2031

P3

Active, not recruiting

Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-06-30

2025-05-06

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

PRO11090340

P2

Recruiting

Crohn Disease

2025-12-01

2019-08-21

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCI-2016-01915

P1

Completed

Acute Lymphoid Leukemia|Lymphoma, B-Cell|Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome|Lymphocytic Chronic B-Cell Leukemia|Blast Crisis|Lymphoma, Non-Hodgkin|Anemia, Aplastic|Leukemia, Plasma Cell|Acute Monocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma|Acute Myelomonocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Juvenile Myelomonocytic Leukemia,|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Myeloproliferative Disorders|Chronic Myeloid Leukemia

2023-02-13

2023-02-18

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

0669-19-FB

P2

Terminated

Multiple Myeloma

2022-12-21

2023-08-30

Primary Endpoints|Start Date|Treatments

NCI-2018-01236

P2

Completed

Preleukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Myelodysplastic Syndrome|Hodgkin Lymphoma|Histiocytosis, Langerhans-Cell|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Myeloid, Accelerated Leukemia|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Anemia, Refractory, with Excess of Blasts|Biphenotypic Acute Leukemia

2022-09-20

2023-06-30

Primary Endpoints

NCI-2013-02183

P2

Completed

Preleukemia|Blast Crisis|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Myeloid, Accelerated Leukemia

2022-02-28

2024-01-18

NCI-2012-02071

P1

Unknown status

Preleukemia|Lymphocytic Chronic B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Biphenotypic Acute Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Multiple Myeloma|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Lymphoma, B-Cell

2021-11-01

2022-02-02

Primary Endpoints|Treatments|Trial Status

Neuroblastoma Protocol 2012

P2

Active, not recruiting

Neuroblastoma

2021-10-21

2024-11-27

Primary Endpoints|Treatments

HAPNK1

P2

Completed

Lymphoma|Leukemia

2021-08-27

2022-11-01

Patient Enrollment|Primary Endpoints|Treatments

AMC-097

P2

Active, not recruiting

Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|T-Cell Lymphoma|Follicular Lymphoma|Mantle-Cell Lymphoma|Burkitt Lymphoma|HIV Infections

2021-05-13

2024-11-27

Primary Endpoints|Treatments

OSU-19190

P2

Terminated

Multiple Myeloma

2021-05-08

2023-09-29

Primary Endpoints

NCI-2016-00477

P2

Completed

Anemia, Refractory, with Excess of Blasts|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Preleukemia

2020-03-01

2024-11-27

Primary Endpoints|Treatments

RADIANT

P1

Completed

Renal Cell Carcinoma|Neuroblastoma|Gastrointestinal Cancer|Rhabdomyosarcoma|Clear Cell Adenocarcinoma|Lymphoma|Rhabdoid Tumor|Melanoma|Wilms Tumor|Clear Cell Sarcoma|Sarcoma, Ewing|Adenomyoepithelioma

2020-02-10

2020-10-20

Primary Endpoints

NCI-2012-03168

N/A

Withdrawn

Immunoblastic Lymphadenopathy|Sezary Syndrome|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Hairy Cell Leukemia|Burkitt Lymphoma|AIDS-Related Lymphoma|Leukemia, Plasma Cell|Adult T-Cell Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Mycosis Fungoides|Extranodal NK-T-Cell Lymphoma|Waldenstrom Macroglobulinemia|T-Cell Peripheral Lymphoma|Diffuse Large B-Cell Lymphoma|Large-Cell Anaplastic Lymphoma|Large Granular Lymphocytic Leukemia|Mantle-Cell Lymphoma|Plasmablastic Lymphoma|T-Cell Cutaneous Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Intraocular Lymphoma

2019-02-01

2024-11-27

Primary Endpoints

NCI-2009-01334

P2

Completed

Prolymphocytic T-Cell Leukemia|T-Cell Lymphoma|Prolymphocytic B-Cell Leukemia|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Leukemia, Plasma Cell|Prolymphocytic Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia

2018-06-30

2024-11-27

Primary Endpoints

ASCIST

P1

Completed

Lymphoma|Neuroblastoma

2017-12-20

2024-11-27

Primary Endpoints

Ewing/Allo

P1

Completed

Sarcoma, Ewing

2016-12-01

2019-03-20

Treatments

11-X335

P2

Withdrawn

Melanoma

2016-02-01

2024-06-26

Primary Endpoints

REFNK1

P2

Terminated

Juvenile Myelomonocytic Leukemia,|Lymphoma, Non-Hodgkin|Sarcoma, Myeloid|Preleukemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myelomonocytic Leukemia

2015-04-01

2019-03-20

ANBL0532

P3

Completed

Neuroblastoma

2015-02-27

2024-11-27

Primary Endpoints